- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01988701
Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease
Lymphocyte Profiles and Activation Status in the Development of Chronic Graft-versus-Host Disease
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To explore and assess changes in subsets and activation status of B-, T,-, and natural killer (NK) lymphocytes in peripheral blood following allogeneic stem cell transplant and how they may be associated with clinical events with an ultimate future goal of conducting a larger successor study to identify potential therapeutic targets based on its findings.
SECONDARY OBJECTIVES:
I. To assess the feasibility of obtaining and comparing patients with chronic graft-versus-host disease (cGVHD) with time-matched stem cell transplant (SCT) patients without cGVHD and identify logistical challenges with obtaining and processing samples in each of the subgroups of interest for these analyses.
II. To assess and explore differences in lymphocyte subsets (B-, T-, and NK) between those with vs. without cGVHD.
III. To assess and explore differences in cytokines in patients with cGVHD vs. those without.
IV. To describe lymphocyte subsets and activation and explore how these may be related to specific clinical manifestations of cGVHD.
OUTLINE:
Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunosorbent spot (ELISPOT), immunoblot, and microarray assays.
Study Type
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Allogeneic SCT groups: Patients who have received stem cell transplantation at The Ohio State University are eligible and who are at or beyond day +75 following allogeneic SCT regardless of previous diagnosis of acute or chronic graft-versus-host disease (GVHD)
- Autologous SCT group: Patients who have received an autologous stem cell transplant at The Ohio State University and who have achieved platelet and neutrophil engraftment
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Allogeneic SCT Groups
Patients who have received stem cell transplantation at The Ohio State University are eligible and who are at or beyond day +75 following allogeneic SCT regardless of previous diagnosis of acute or chronic GVHD.
|
Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
Other Names:
|
Autologous SCT group
Patients who have received an autologous stem cell transplant at The Ohio State University and who have achieved platelet and neutrophil engraftment.
|
Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subsets and activation status of B, T, and NK lymphocytes
Time Frame: Up to 2 months
|
Side by side box plots with overlaid plotted points will be used to assess potential differences in continuous markers between groups.
|
Up to 2 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Logistical challenges with obtaining and processing samples in each of the subgroups of interest
Time Frame: Up to 2 months
|
Up to 2 months
|
Differences in lymphocyte subsets (B, T, and NK) between those with vs. without cGVHD
Time Frame: Up to 2 months
|
Up to 2 months
|
Differences in cytokines in patients with cGVHD vs. those without
Time Frame: Up to 2 months
|
Up to 2 months
|
Differences in in lymphocyte activation between those with vs. without cGVHD
Time Frame: Up to 2 months
|
Up to 2 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Samantha Jaglowski, MD, Ohio State University Comprehensive Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OSU-12208
- NCI-2013-01641 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic/Lymphoid Cancer
-
Leland MethenyAvailableHematopoietic/Lymphoid CancerUnited States
-
ImCheck TherapeuticsRecruitingHematopoietic/Lymphoid Cancer | Solid Tumor, AdultFrance, Belgium, United States, Germany, Spain, United Kingdom
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedHematopoietic/Lymphoid CancerUnited States
-
M.D. Anderson Cancer CenterAmgenTerminatedHematopoietic/Lymphoid Cancer | Richter's TransformationUnited States
-
University of Colorado, DenverPatient-Centered Outcomes Research InstituteCompletedHematopoietic/Lymphoid CancerUnited States
-
Cancer Research UKUnknownHematopoietic/Lymphoid CancerUnited Kingdom
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedPain | Hematopoietic/Lymphoid CancerUnited States
-
University of California, San FranciscoSwim Across AmericaRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Childhood CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Cancer | SurvivorshipUnited States
-
Assistance Publique Hopitaux De MarseilleUnknownHematopoietic/Lymphoid CancerFrance
Clinical Trials on Ancillary-Correlative
-
Medical University of South CarolinaCompletedProstate CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingHematologic MalignancyUnited States
-
Assaf-Harofeh Medical CenterUnknownSevere Bacterial Infection | Febrile ShiveringIsrael
-
Novartis PharmaceuticalsCompletedAdvanced Solid and Hematological TP53wt TumorsFrance, Netherlands, Spain, Germany, Singapore, Japan, Taiwan, United States
-
University Hospital, Clermont-FerrandGroupe LépineCompletedTotal Hip Replacement | CoxarthrosisFrance
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedLeukemiaUnited States, Canada, Australia, Switzerland, Puerto Rico, Netherlands
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingDepression | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Anxiety Disorder | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Peking UniversityChina development research foundationNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisActive, not recruiting
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States